Krystal Biotech, Inc.
KRYS
Rank in Stocks
#2137
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Share Price
$325.70
Market Cap
$9.64B
Change (1 day)
1.70%
Change (1 year)
66.20%
Country
US
Trade Krystal Biotech, Inc. (KRYS)
Category
Healthcare
Revenue for Krystal Biotech, Inc. (KRYS)
Revenue in Jun 2026 TTM: $440.48M
According to Krystal Biotech, Inc. latest financial reports the company's current revenue (TTM) is $440.48M. In 2023 the company made a revenue of $50.70M an increase over the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Krystal Biotech, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $440.48M | 51.62% |
| 2024 | $290.52M | 473.02% |
| 2023 | $50.70M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $1.03M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 2,766.01% |
US
|
|
| $2.23B | 405.81% |
US
|
|
| $15.74B | 3,474.32% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,266.97% |
NL
|
